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Abstract Bispecific antibodies extend the capabilities of nature
and might be applied in immunotherapy and biotechnology. By
fusing the gene of a single-chain Fv (scFv) fragment to a helical
dimerization domain, followed by a second scFv fragment of
different specificity, we were able to express a functional protein
in E. coli, which is bispecific and has two valencies for each
specificity. The dimeric bispecific (DiBi) miniantibody preserves
the natural avidity of antibodies in a very small-sized molecule of
only 120 kDa. The generality of the principle was shown with a
scFv fragment binding the EGF-receptor (named scFv 425) in
three combinations with scFv fragments either directed against
CD2 (ACID2.M1), phosphorylcholine (McPC603) or fluorescein
(FITC-E2). Binding was analyzed by sandwich surface plasmon
resonance biosensor (BIAcore) measurements.
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1. Introduction
In natural antibodies the Fc part is utilized as the second
e¡ector site and also serves to dimerize the antigen binding
sites. A potentially much wider scope of applications becomes
accessible by engineered antibody constructs with two di¡er-
ent speci¢cities. So far, most of the bispeci¢c antibodies have
been produced as hybrid hybridoma IgG [1] or chemically
crosslinked [2] molecules, which assemble as heterodimeric
molecules with one binding site for each speci¢city. However,
this approach results in the loss of avidity, also named func-
tional a⁄nity, which arises from the simultaneous binding to
two antigens. Depending on the spatial arrangement of the
antigen binding sites as well as the antigen surface distribu-
tion, the avidity can be signi¢cantly higher than the intrinsic
a⁄nity [3,4]. In addition, divalency is required for several bio-
logical functions such as receptor crosslinking on cell surfaces.
For some antibody action divalency is therefore essential [5].
Furthermore, for therapeutic approaches the presence of an
Fc domain might not always be desired. We therefore con-
structed a miniantibody, consisting of four single-chain (scFv)
fragments and a dimerization domain, which is at the same
time bispeci¢c and bivalent for each speci¢city.
Bispeci¢c antibodies have been considered as useful agents
for example in the treatment of cancer. They can bind with
one side to a tumor cell and with the second speci¢city to
immune e¡ector cells, which are thereby redirected against
the tumor, or further molecules of pharmacological interest.
Several markers on tumor cells (e.g. EGF-R, HER-2/neu, Ep-
CAM/EGP-2, CEA, CD19, CD30) and on immune cells (e.g.
CD2, CD3, CD16, CD64) have been investigated for this
purpose [6]. The immune therapy approach with bispeci¢c
antibodies has come of age and is already evaluated in clinical
trials [7].
For targeting of tumors overexpressing the epidermal
growth factor receptor (EGF-receptor), such as the head
and neck tumor, the well characterized murine IgG2a anti-
body 425 is a promising molecule. It binds to the EGF-recep-
tor while preventing growth stimulation [8] and has already
been used in clinical trials [9,10]. We utilize a scFv fragment
[11^13] derived from the monoclonal antibody 425 [14] for
designing bispeci¢c molecules. For the potential redirection
of cytotoxic T-cells and natural killer cells, a scFv fragment
has been used which binds CD2 and has been derived from a
monoclonal antibody named ACID2.M1 [15^17]. To test the
generality of this concept of combining various speci¢cities
two additional model scFv fragments have been studied in a
fusion protein together with the 425 scFv fragment. One is
derived from the monoclonal antibody McPC603 [18,19],
which binds the hapten phosphorylcholine, and has been en-
gineered for improved in vivo expression [20]. The other scFv
fragment is named FITC-E2, binds FITC, and has been de-
rived from a phage display library [21]. As a dimerization
domain we used a helix-loop-helix motif, based on designed
peptides [22], which has been shown previously to work well
for the functional dimerization of miniantibodies [23,24].
Here we demonstrate that a protein resulting from a gene
fusion of a scFv fragment to a helix-loop-helix motif and
further to a second scFv fragment can be functionally ex-
pressed in E. coli. We show that the molecule is both bispeci¢c
and shows avidity resulting from divalency for each speci¢c-
ity. As expression and puri¢cation worked with all three com-
binations of speci¢cities tested so far, the fusion strategy pre-
sented might be applicable to a wide range of scFv fragments.
2. Materials and methods
2.1. Plasmid construction
The expression vector was based on pASK30 [25], in which the
XbaI/HindIII cassette has been replaced by an insert as shown in
Fig. 1B and C. The new vector was assembled in the ¢rst step
from the plasmids pACK9-9p53his and pACKdhlxAscI (P. Pack,
unpublished) to give the intermediate plasmid pKM309-9dhlxhis2.
In this plasmid, a scFv fragment binding CD2, named M1, with a
preceding pelB leader sequence was cloned from the plasmid
pEG3M1FH (W. Strittmatter, unpublished) via XbaI/EcoRI to give
pKM30M1dhlxhis2. As the second, C-terminal speci¢city a scFv frag-
ment binding EGF-receptor, named 425 [14], was ampli¢ed from the
plasmid pFEG1T (W. Strittmatter, unpublished) by PCR with add-on
tails on both sides containing AscI sites using the primers ak425_1:
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AGGCGCGCCG GAAGTGCAAC TGCAGCAGTC and ak425_1-
rev: AGGCGCGCCC CGTTTGATCT CGAGTTCTG. The PCR
fragment was cloned via the AscI sites to give plasmid
pKM30M1dhlx425h. To test additional N-terminal speci¢cities the
scFv fragment M1 was replaced via XbaI/EcoRI by two further
scFv fragments. First, a scFv fragment binding phosphorylcholine,
named McPC603_H11_L, which is preceded by an ompA signal se-
quence, contains three stabilizing mutations (H11) [20], a long glycine-
rich linker of 25 amino acids (L) and was taken from the plasmid
pKA30H11-25 to give pKM30PCLdhlx425. Second, in an improved
vector (see below), scFv M1 was replaced by a scFv fragment binding
£uorescein, named FITC-E2 [21], which was ¢rst subcloned in
pAK500 via S¢I [26], to give pKM310Fitcdhlx425h.
The improved vector was constructed containing a minimal hok/sok
system [27] for killing of plasmid-free cells, and the skp gene [28]
for higher product yield. First the hok/sok was ampli¢ed by PCR
using the primers hoksok: TCGGAAGATC TCCCGGGACA AAC-
TCCGGGA GGCAGC, and hoksok_rev: TCGGAAGATC TCAA-
CATCAG CAAGGAGAAA GG. Both primers carried a BglII site
and the ¢rst primer an additional SmaI site as add-on tail. The BglII
hok/sok fragment was cloned into a BamHI site behind the lpp termi-
nator of the scFv fragment in the plasmid pAK100 [26] to give
pKM100hs. The skp gene was cloned as SpeI/SpeI insert ¢lled with
Klenow fragment from plasmid pHB112 [28] in the newly established
SmaI site to give pKM100hsskp. The hok/sok-skp insert was cloned
via HindIII/BsaI in the pKM30 series to give pKM310, thus resulting
in pKM310M1dhlx425h. All PCR steps were veri¢ed by sequencing
and all cloning steps by analytical restriction digests.
2.2. Protein expression
Plasmids were transformed either into E. coli JM83 (F3 ara (lac-
proAB) rpsL (strr) [x80dlac v(lacZ)M15] thi) or BF18-61 (R. Wen-
deroth, unpublished), a RV308 (lac74-galISII: :OP308-strA) deriva-
tive. Protein expression was carried out in LB broth in shake £asks,
containing 0.1 g/l ampicillin. Overnight cultures were grown at 26‡C.
The main culture was inoculated to an OD550 of 0.15 (typical dilution
of 1:25^1:30) and grown at 24‡C. Cells were induced at an OD550 of
0.5 to 0.6 and harvested by centrifugation at 5000Ug after 4 h. Cell
pellets were immediately frozen at 380‡C and stored until use.
2.3. Protein puri¢cation
Cell pellets were thawed in a seven-fold volume of PBST (50 mM
Na-phosphate, 150 mM NaCl, 0.005% Tween-20) containing 10 mM
imidazole at pH 7.4 in case of the miniantibodies M1dhlx425 and
FITCE2dhlx425, and in BBST bu¡er (200 mM H3BO3, 160 mM
NaCl, 0.005% Tween-20, adjusted to pH 8.0 with NaOH) in case of
the miniantibody PCLdhlx425. Cells were disrupted by soni¢cation
three times with continuous temperature monitoring in an ice-ethanol
bath between 3 and 10‡C. The DiBi miniantibodies containing scFv
M1 and scFv FITC-E2 miniantibodies were puri¢ed by immobilized
metal ion a⁄nity chromatography (IMAC) using Ni-NTA super£ow
material (Qiagen, Germany). After washing steps with 12 mM and 30
mM imidazole the protein was eluted at 250 mM imidazole in PBST
bu¡er, pH 7.4. After IMAC the miniantibody FITCE2dhlx425 was
dialyzed against PBST with 1 mM EDTA and a second time against
PBST and used for analysis. The miniantibody M1dhlx425 was fur-
ther puri¢ed using thiophilic adsorption chromatography. In this case,
3 M (NH4)2SO4 was added to the IMAC-eluted sample to a ¢nal
concentration of 1 M. The protein was loaded on a thioether column
(Fractogel EMD TA, Merck Darmstadt, Germany), washed with 500
mM (NH4)2SO4 in PBS and eluted with 150 mM (NH4)2SO4 in PBS
bu¡er. The sample was dialyzed against PBST bu¡er. The minianti-
body PCLdhlx425 was puri¢ed by phosphorylcholine a⁄nity chroma-
tography as described [29,30] in borate bu¡ered saline (BBS) with a
washing step with bu¡er containing 1 M NaCl and elution with 20
mM PC. In addition, miniantibodies have also been puri¢ed by anti-
425 anti-idiotypic immunoa⁄nity chromatography [17].
2.4. SDS-PAGE and size exclusion chromatography
Protein samples were analyzed by SDS-PAGE (12% mini-gels with
5% stacking gels) and stained with Coomassie Brilliant Blue according
to standard methods. The size exclusion chromatography column
(Superose-12 PC3.2/30, Pharmacia, Sweden) was run with a SMART
system (Pharmacia, Sweden) and calibrated with a molecular weight
standard (cytochrome c, 12.4 kDa; carbonic anhydrase, 29 kDa; al-
cohol dehydrogenase, 150 kDa; L-amylase, 200 kDa) (Sigma, USA).
Samples of 20 Wl were injected, the running bu¡er was PBST, and
elution was monitored at 280 nm and 254 nm.
2.5. Analysis of binding
Binding capabilities of the miniantibodies were analyzed with a
BIAcore instrument (Biacore, Sweden) [31]. FITC (Fluorescein iso-
thiocyanate) (Fluka, Switzerland) was coupled to BSA (Imject, Pierce,
USA) at a molar ration of 3 to 1 to give BSA-FITC using a standard
procedure [32] and dialyzed against PBS bu¡er. Phosphorylcholine,
coupled to the tyrosines of BSA and prepared according to [23], was
taken from the lab stock. EGF-receptor (EGF-R) extracellular do-
main was kindly provided by Dr. W. Strittmatter (Merck KGaA).
BSA-FITC and EGF-R were diluted in 10 mM Na-acetate, pH 4.5
to a ¢nal concentration of approximately 0.2 mg/ml and 70 Wl were
coupled to a CM5 sensor chip (Biacore, Sweden) using standard EDC
(1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide-HCl) NHS (N-hy-
droxysuccinimide) coupling chemistry with subsequent blocking by
ethanolamine. Running bu¡er for the BIAcore was PBST in the
case of the miniantibodies M1dhlx425 and FITCE2dhlx425, and
BBS bu¡er with 0.005% Tween for the miniantibody PCLdhlx425.
Surfaces were regenerated with a glycine/HCl bu¡er (100 mM glycine,
500 mM NaCl, adjusted to pH 2.8 with HCl).
3. Results
3.1. Plasmid construction, expression and puri¢cation
The concept of homodimerizing scFv fragments via a fused
homodimerization domain, named miniantibodies, was ex-
tended by fusing a second scFv fragment behind the homo-
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Fig. 1. Model of a dimeric bispeci¢c (DiBi) miniantibody (A),
scheme of the gene arrangement (B), and sequence of the dhlx dime-
rization domain [23] with its adjacent hinge regions (C). A: The
protein model was composed from a minimized structure of a varia-
ble domain (PDB ¢le 4FAB) to which a linker was attached, a
hinge region modeled in extended conformation, a preliminary
structure of a designed helix-loop-helix motif with sequence similar
to the actually used domain (kindly provided by W.F. DeGrado), a
linker (the second hinge) modeled in extended conformation, and ¢-
nally the variable domains again. B: The gene depicts the modular
arrangement of the dimeric bispeci¢c miniantibody including singu-
lar restriction sites, which was cloned into various vectors. The scFv
fragments used all have VH-linker-VL orientation. C: A part of the
amino acid sequence of a DiBi miniantibody is shown.
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dimerization domain (Fig. 1). Unique restriction sites £anking
each domain facilitate easy combination of various scFv frag-
ments of di¡erent speci¢city, giving convenient access to sev-
eral dimeric bispeci¢c (DiBi) miniantibodies. This concept has
been tested with three di¡erent N-terminal scFv fragments: a
better folding variant of the scFv fragment McPC603 [19]
with a 25-mer linker, named PCL, which binds phosphoryl-
choline, the scFv FITC-E2 [21], which binds £uorescein, and
the scFv ACID2.M1 [16], named M1, which binds CD2.
These are followed by a murine IgG3 upper hinge and a
helix-loop-helix (dhlx) dimerization domain [23]. As the C-
terminal speci¢city we used the scFv fragment 425 [14], which
binds to the EGF-receptor.
All three miniantibodies were directed to the periplasm with
a PelB or OmpA signal sequence. Functional protein could be
puri¢ed from crude cell lysates by a⁄nity chromatography
(Fig. 2A) or by a combination of IMAC and thiophilic ad-
sorption chromatography (Fig. 2B). The thiophilic adsorption
chromatography worked well with two out of three minianti-
bodies tested, including miniantibody M1dhlx425. Typical
yields of puri¢ed protein were 100 Wg l31 OD31 from E.
coli shake £ask culture.
3.2. Protein analysis
The dimeric nature of the bispeci¢c scFv constructs was
determined by size exclusion chromatography. The DiBi mini-
antibody M1dhlx425 had an apparent molecular weight of
144 kDa and the DiBi miniantibody PCLdhlx425 one of
140 kDa, which is consistent with the calculated weight of
about 120 kDa (Fig. 3). For comparison, the monospeci¢c
miniantibodies 425dhlx and M1dhlx, dimerized via the dhlx
domain, but not carrying the C-terminal scFv, were also in-
vestigated and corresponded to the expected mass of 67 and
66 kDa, respectively [17].
To analyze the bispeci¢city of the miniantibodies a sand-
wich assay was performed by immobilizing either the antigen
of the ¢rst or the second antibody on a BIAcore biosensor
chip. Upon binding of the miniantibody, the signal (measured
in resonance units (RU)) increased as expected, and when the
second antigen was added, a further increase in the signal was
seen (Fig. 4A, B). As an example, the antigen of the N-termi-
nal scFv fragment, BSA-FITC, was immobilized. When EGF-
receptor was injected alone onto this surface as a control, only
a background signal (20 RU) was obtained (Fig. 4A, phase I).
Injection of a DiBi miniantibody comprising an anti-FITC
and an anti-EGF-R scFv fragment resulted in a signi¢cant
signal (1400 RU, Fig. 4A, phase II). When the bulk e¡ect
(due to change in the bu¡er composition) had passed, a stable
binding of the scFv FITC-E2 was seen, which is a result of its
high a⁄nity [21], further ampli¢ed by the high coating density
of the FITC-BSA, and the bivalent binding (phase III). In-
jection of EGF-receptor extracellular domain onto the bound
DiBi miniantibody (phase IV) gave then rise to another in-
crease in signal, due to association of this antigen to the DiBi
miniantibody, which stopped at the end of injection (addi-
tional 480 RU), and was followed by a dissociation phase
of the EGF-receptor (phase V).
Three points from these results are to be noted. First, the
DiBi miniantibody is indeed functionally bispeci¢c. Second,
the anti-EGF-R scFv 425 is C-terminal in the construct, and
thus both variable domains of this scFv are blocked by linkers
at their respective N-termini, but it is still able to bind a large
(approx. 100 kDa) molecule. Third, in this situation the EGF-
R is bound only monovalently, which results in a higher o¡-
rate (phase V) than when it is bivalently bound (see below). A
control experiment, in which an anti-425 idiotypic monoclonal
antibody was injected instead of the EGF-R antigen con-
¢rmed bispeci¢city as well (data not shown).
Immobilization of the antigen of the C-terminal scFv is
exempli¢ed in Fig. 4B with the anti-PC-anti-EGF-R DiBi
miniantibody. EGF-receptor was immobilized and the DiBi
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Fig. 3. Determination of protein size by size exclusion chromatogra-
phy. Samples of 20 Wl were injected onto a Superose-12 column,
and the molecular weight was determined according to a calibration
curve of markers shown on top.
Fig. 2. SDS-PAGE of the puri¢cation of (A) the DiBi miniantibodies PCLdhlx425 by PC a⁄nity chromatography and (B) the DiBi minianti-
body M1dhlx425 by IMAC and thiophilic adsorption chromatography (TAC). A: Lane M, marker; lane 1, crude lysate; lane 2, centrifugation
supernatant; lane 3, £ow through; lanes 4^5, PC elution fractions. B: Lane M, marker; lane 1, sample eluted from IMAC; lane 2, sample sup-
plemented with 1 M (NH4)2SO4 ; lanes 3^4, wash fractions at 500 mM (NH4)2SO4 ; lanes 5^8, fractions of the TAC elution peak at 150 mM
(NH4)2SO4 ; lanes 9^10, residual protein eluting in pure PBS bu¡er; lane 11, column wash with H2O. Arrows indicate the size of the DiBi min-
iantibody band.
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miniantibody bound as expected. Dissociation was slow (Fig.
4B, phase II), presumably since the binding was bivalent and
the intrinsic binding to EGF-R is tight. Injecting BSA-PC on
this DiBi miniantibody resulted in a further signal increase
(phase III). The comparatively small increase can be explained
by each BSA molecule carrying on average seven PC mole-
cules (data not shown), which results in a high valency of a
single BSA-PC molecule, reducing the total number of bound
BSA-PC molecules. The high avidity of bound BSA-PC is also
evidenced by the slow dissociation (phase IV), despite the
intrinsically very fast o¡-rate of 10 to 38 s31 of PC from
the antibody McPC603 [33]. That this binding is nevertheless
very speci¢c is demonstrated by the fact that soluble PC can
displace bound BSA-PC immediately (phase V and VI), since
the stable binding of the latter is caused by multivalency, and
PC can interfere with the highly dynamic binding (see also
[4,34]).
Finally, the binding of the miniantibody M1dhlx425 to the
EGF-R was analyzed to visualize the bivalent binding behav-
ior using a range of miniantibody concentrations (25 nM to
1600 nM) and a surface coated with 1600 RU EGF-R (Fig.
4C). Measurements under identical conditions were performed
with a monovalent, CHCL-heterodimerized miniantibody con-
taining scFv M1 and 425 (some curves are shown for compar-
ison in Fig. 4C), the homodimeric miniantibody 425dhlx, and
the monoclonal antibody 425, which all have been published
previously [17]. The comparison of these series reveals that the
C-terminal scFv in the DiBi miniantibody binds comparably
to the parental monoclonal antibody, but dissociates much
more slowly than the monovalent constructs, suggesting a
signi¢cant contribution of bivalent binding.
4. Discussion
The results presented here demonstrate that bivalent and
bispeci¢c scFv-based molecules can be obtained in functional
form E. coli by encoding two scFv fragments in a single pep-
tide. Furthermore, a helix-loop-helix motif encoded in the
same peptide leads to homodimerization, resulting in tetrava-
lent species with two speci¢cities (Fig. 1). Up to now, expres-
sion in E. coli of two scFv fragments in a single peptide chain
was mainly achieved by cytoplasmic inclusion bodies [35], and
it was even noted, depending on the antibody, that functional
expression can be impossible, while some of the molecules can
still be produced in mammalian expression systems [36]. How-
ever, the three DiBi miniantibodies described here demon-
strate that the functional expression approach is feasible.
We think that three factors may account for this success.
First, the scFv fragments on their own need to be well ex-
pressed, and scFv fragments with a high tendency to form
aggregates in the periplasm are unfavorable candidates for
more complex fusion proteins. Second, we speculate that the
additional dimerization domain might serve as structured
spacer between the scFv fragments, thereby reducing intra-
molecular aggregation and incorrect domain swapping. Third,
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Fig. 4. BIAcore sensorgrams demonstrating the bispeci¢city (A, B)
and avidity (C) of the DiBi miniantibodies. A: BSA-FITC was
coupled to the surface and the anti-FITC-anti-EGF-R miniantibody
was tested. Phase I, injection of EGF-receptor (control); II, injec-
tion of DiBi miniantibody FITCE2dhlx425; III, dissociation of DiBi
miniantibody; IV, injection of EGF-receptor; V, dissociation of
EGF-receptor. B: EGF-receptor was coupled to the surface and the
anti-PC-anti-EGF-R miniantibody was tested; phase I, injection of
DiBi miniantibody PCLdhlx425; II, dissociation of DiBi minianti-
body; III, injection of BSA-PC; IV, dissociation of BSA-PC and
DiBi miniantibody; V, injection of 20 mM PC (large bulk e¡ect)
causing BSA-PC elution; VI, signal after PC has been washed out.
C: Anti-CD2-anti-EGF-R DiBi miniantibody M1dhlx425 was in-
jected at increasing concentrations (25, 50, 100, 200, 400, 800, 1600
nM) onto a surface with EGF-receptor coupled to 1600 RU. Phase
I, injection of M1dhlx425; II, dissociation; III, regeneration with
Gly/HCl. For comparison, the data of a monovalent, CHCL-hetero-
dimerized miniantibody containing scFv 425 and M1, measured
under identical conditions (25, 100, 400, 1600 nM) on the same chip
[17], are shown as dotted lines.
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e⁄cient puri¢cation schemes with high speci¢city and low
product loss are essential. Of course, antigen or anti-idiotypic
immunoa⁄nity puri¢cation are most advantageous, but de-
pending on the scFv fragments involved, thiophilic adsorption
chromatography has also been found useful. A combined
IMAC/anti-His-tag immunoa⁄nity puri¢cation may provide
a general strategy [37].
The idea of bispeci¢c antibodies is associated with high
expectations for therapeutic applications, and thus basic sci-
ence has striven for a long time for a facile generation of these
molecules [38]. Therefore, various methods are already avail-
able such as the hybrid hybridoma technology [1], the chem-
ical crosslinking of Fab fragments [2], diabodies consisting of
dimerized scFv fragments [39], scFv fused to leucine zipper
domains [40], scFv fused to whole antibodies [41], and CHCL-
heterodimerized scFv [17]. Nonetheless, our dimeric bispeci¢c
miniantibody concept features two advantageous properties.
To our knowledge it is currently the smallest available anti-
body-based molecule to combine bispeci¢city with the avidity
of two binding sites, which are, moreover, connected via £ex-
ible linkers. Depending on the application, size is an impor-
tant factor, for example for tissue penetration of molecules
circulating in the bloodstream. Bivalent binding can be im-
portant in several aspects. Bivalent binding increases avidity,
which can compensate for weak binding, but might also be
used to increase selectivity for targets with multiple antigen
display, such as tumor cells overexpressing certain markers.
Furthermore, bivalent binding is often required for receptor
crosslinking and subsequent signal transduction. Thus, we
believe that the dimeric bispeci¢c miniantibody is a valuable
tool for research and a format suitable for future clinical test-
ing.
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